Literature DB >> 20888257

Impact of lung transplantation on serum lipids in adults with cystic fibrosis.

Edward F Nash1, Anne Stephenson, Emma J Helm, Peter R Durie, Elizabeth Tullis, Lianne G Singer, Cecilia Chaparro.   

Abstract

BACKGROUND: Cystic fibrosis (CF) is an inherited condition that causes progressive respiratory failure and is the third most common indication for adult bilateral lung transplantation. Post-transplant hyperlipidemia commonly affects lung transplant recipients, but the impact of lung transplantation on serum lipids in the adult CF population is not well studied. The aim of this study was to examine the impact of lung transplantation on the prevalence of hyperlipidemia in CF adults.
METHODS: We retrospectively analyzed prospectively collected data in 108 CF adults undergoing bilateral sequential lung transplantation from 1996 to 2007 at our institution.
RESULTS: The prevalence of hypercholesterolemia (>5.2 mmol/liter) and hypertriglyceridemia (>2.2 mmol/liter) increased significantly after lung transplant (14.8% vs 32.4%, p = 0.002; 8.3% vs 41.7%, p < 0.0001, respectively). Cyclosporine A (CsA) use was associated with significantly higher post-transplant total and LDL cholesterol compared with tacrolimus use. Post-transplant calculated Framingham risk score was <10% in all but 1 subject.
CONCLUSION: Hyperlipidemia was common in our cohort of post-lung transplant CF adults, with a higher prevalence in those receiving CsA. Despite these findings, calculated cardiovascular risk remained low and none of these subjects developed clinically evident cardiovascular disease.
Copyright © 2011 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20888257     DOI: 10.1016/j.healun.2010.08.024

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  7 in total

Review 1.  Post-transplant dyslipidemia: Mechanisms, diagnosis and management.

Authors:  Arnav Agarwal; G V Ramesh Prasad
Journal:  World J Transplant       Date:  2016-03-24

Review 2.  Central modulation of cyclosporine-induced hypertension.

Authors:  Hanan M El-Gowelli; Mahmoud M El-Mas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-11-29       Impact factor: 3.000

3.  Biopharmaceutical Evaluation of Novel Cyclosporine A Nano-matrix Particles for Inhalation.

Authors:  Hideyuki Sato; Hiroki Suzuki; Keisuke Yakushiji; Jennifer Wong; Yoshiki Seto; Robert K Prud'homme; Hak-Kim Chan; Satomi Onoue
Journal:  Pharm Res       Date:  2016-05-25       Impact factor: 4.200

Review 4.  Nutritional Requirements of Lung Transplant Recipients: Challenges and Considerations.

Authors:  Valerie Jomphe; Larry C Lands; Genevieve Mailhot
Journal:  Nutrients       Date:  2018-06-19       Impact factor: 5.717

5.  Dyslipidemia in racially admixtured children with cystic fibrosis.

Authors:  Cresio Alves; Daniela Lima; Mauricio Cardeal; Angelica Santana
Journal:  Indian J Endocrinol Metab       Date:  2012-07

6.  Pretransplant dyslipidaemia determines outcome in lung transplant recipients.

Authors:  Urs Wenger; Silvia R Cottini; Georg Noll; Stefan Arndt; Paul A Stehberger; Stefanie Klinzing; Reto A Schuepbach; Markus Béchir
Journal:  Lipids Health Dis       Date:  2013-04-23       Impact factor: 3.876

Review 7.  Cystic fibrosis related liver disease--another black box in hepatology.

Authors:  Katharina Staufer; Emina Halilbasic; Michael Trauner; Lili Kazemi-Shirazi
Journal:  Int J Mol Sci       Date:  2014-08-04       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.